Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
复制标题
DOI：
10.1093/annonc/mdy275
复制
发表时间：
2018-10-01
影响因子：
50.5
通讯作者：
Peters, S.
中科院分区：
文献类型：
--
作者：
Planchard, D.;Popat, S.;Peters, S.
原发肺癌仍然是仅次于非黑素细胞皮肤癌的最常见的恶性肿瘤，肺癌的死亡人数超过了全世界任何其他恶性肿瘤[1]。2012年，肺癌是男性中最常见的癌症，据估计，全球有120万例肺癌病例。在女性中，肺癌是较发达国家癌症死亡的首要原因，在欠发达国家是第二大癌症死亡原因[1]。发病率最高的是中欧/东欧和亚洲，年龄标化发病率分别为53.5/10万和50.4/10万。欧洲对2017年的预测显示，5年内下降10.7%，男性发病率为33.3/10万，女性发病率上升5.1%，发病率为14.6/10万[2]。与美国相反，欧洲的女性死亡率正在上升[3]。据估计，2017年欧洲与肺癌相关的死亡人数是男女癌症死亡的主要原因，分别占男性的24%和女性的15%[2]。非小细胞肺癌(NSCLC)占肺癌的80%-90%，而小细胞肺癌(SCLC)在过去20年里在许多国家的发病率一直在下降[4]。在过去的25年里，NSCLC的组织类型的分布发生了变化：在美国，以前的主要组织类型鳞状细胞癌(SCC)减少了，而腺癌在男女之间都有所增加。在欧洲，类似的趋势也出现在男性中，而在女性中，鳞癌和腺癌仍在增加[5]。
Primary lung cancer remains the most common malignancy after non-melanocytic skin cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1]. In 2012, lung cancer was the most frequently diagnosed cancer in males with an estimated 1.2 million incident cases worldwide. Among females, lung cancer was the leading cause of cancer death in more developed countries and the second leading cause of cancer death in less developed countries [1]. The highest incidence is found in Central/Eastern Europe and Asia with age-standardised incidence rates of 53.5 and 50.4 per 100 000, respectively. European projections for 2017 indicate a 10.7% drop in 5 years with an incidence of 33.3/100 000 in males and a rise of 5.1% and an incidence of 14.6/100 000 in females [2]. Contrary to the United States, the death rate in females is increasing in Europe [3]. The number of lung cancer-related deaths in Europe for 2017 is estimated to represent the leading cause of cancer deaths in both genders, accounting for 24% in males and 15% in females, respectively [2].Non-small cell lung cancer (NSCLC) accounts for 80%–90% of lung cancers, while small cell lung cancer (SCLC) has been decreasing in frequency in many countries over the past two decades [4]. During the last 25 years, the distribution of histological types of NSCLC has changed: in the United States, squamous cell carcinoma (SCC), formerly the predominant histotype, decreased, while adenocarcinoma has increased in both genders. In Europe, similar trends have occurred in men, while in women, both SCC and adenocarcinoma are still increasing [5].